Company profile for Kadimastem

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

At Kadimastem we envision being a global leader in cell therapy. Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based pr...
At Kadimastem we envision being a global leader in cell therapy. Our passion and commitment keep us moving forward, to develop innovative regenerative therapies for incurable diseases. Our goal is to treat millions of patients around the world with that technology. Kadimastem (TASE:KDST) is a clinical stage biotechnology company, with a unique platform for cell therapy that enables the production of off-the-shelf cell-based products for the treatment of unmet medical needs.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Israel
Address
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona
Telephone
Telephone
+972-73-797-1600
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/nls-pharmaceutics-ltd-and-kadimastem-ltd-announce-completion-of-merger-302600312.html

PR NEWSWIRE
30 Oct 2025

https://www.prnewswire.com/news-releases/nls-pharmaceutics-and-kadimastem-announce-completion-of-material-conditions-precedent-for-merger-transaction-and-delisting-date-of-kadimastems-shares-302598112.html

PR NEWSWIRE
29 Oct 2025

https://www.prnewswire.com/news-releases/nls-pharmaceutics-and-kadimastem-highlight-continued-bird-foundation-support-for-itol-102-diabetes-program-following-merger-302598239.html

PR NEWSWIRE
29 Oct 2025

https://www.prnewswire.com/news-releases/nls-pharmaceutics-and-kadimastem-announce-strategic-collaboration-between-kadimastem-and-targetgene-to-advance-next-generation-gene-edited-cell-therapies-302595227.html

PR NEWSWIRE
27 Oct 2025

https://www.prnewswire.com/news-releases/nls-and-kadimastem-announce-receipt-of-nasdaq-approval-merger-expected-to-close-on-october-30-2025-302592675.html

PR NEWSWIRE
23 Oct 2025

https://www.prnewswire.com/news-releases/nls-pharmaceutics-shareholders-approve-merger-with-kadimastem-and-related-proposals-at-extraordinary-general-meeting-302570495.html

PR NEWSWIRE
30 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty